U.S. Rests Its Case in the Elizabeth Holmes Trial

Defense lawyers are expected to argue that the founder of Theranos, the blood-testing start-up, failed but did not commit fraud.,

Advertisement

Continue reading the main story

SAN JOSE, Calif. — For the past 11 weeks, prosecutors revealed emails from desperate investors. They held up falsified documents side-by-side with the originals. They called dozens of witnesses who lobbed accusations of deceit and evasiveness.

And on Friday, after questioning their 29th witness, prosecutors concluded their arguments against Elizabeth Holmes, the founder of the failed blood testing start-up Theranos. Ms. Holmes has pleaded not guilty to 11 counts of defrauding investors over Theranos’s technology and business, in a case that has been billed as a referendum on Silicon Valley’s start-up culture.

The prosecution’s resting its case is a major turning point in the trial of Ms. Holmes, whose rise and fall captivated the public and who has been held up as a symbol of the tech industry’s hubris and the last decade’s culture of grift.

For weeks, prosecutors sought to paint Ms. Holmes, 37, as a liar who built Theranos into a $9 billion start-up while knowing all along that the company’s blood tests, which were trumpeted as revolutionary, didn’t work. Prosecutors methodically outlined six main areas of Ms. Holmes’s deception, including lies about Theranos’s work with the military and pharmaceutical companies, its business performance and the accuracy of its blood tests.

Her lawyers are now expected to argue that Theranos was merely a failure and not a fraud, raising the question of whether Ms. Holmes will take the stand in her own defense. In filings, her lawyers have indicated that she is likely to testify.

The stakes of the trial are high. If Ms. Holmes is convicted, she faces up to 20 years in prison for each count of fraud, and prosecutors may be emboldened to go after more start-ups that stretch the truth to raise funding. An acquittal could send a message that Silicon Valley start-ups, which have exploded in power and wealth over the last decade, are difficult to hold to account.

“When prosecutors rest their case, they are basically saying they have enough to ask the jury to convict the defendant right then and there,” said Andrey Spektor, a lawyer at Bryan Cave Leighton Paisner and former federal prosecutor in New York’s Eastern District. He said he expected the defense to put on a case, rather than simply allow the jury to decide whether the prosecutors failed to prove theirs.

Who’s Who in the Elizabeth Holmes Trial

Erin Woo

Erin Woo?Reporting from San Jose, Calif.

Who’s Who in the Elizabeth Holmes Trial

Erin Woo

Erin Woo?Reporting from San Jose, Calif.

Carlos Chavarria for The New York Times

Elizabeth Holmes, the disgraced founder of the blood testing start-up Theranos, stands trial for two counts of conspiracy to commit wire fraud and nine counts of wire fraud.

Here are some of the key figures in the case ->

Nov. 15, 2021

Item 1 of 9

Ms. Holmes, a Stanford University dropout who founded Theranos in 2003 and raised $945 million from investors, was indicted on fraud charges in 2018. Her case has been plagued for years by delays: First over process, then the pandemic and finally, Ms. Holmes’s giving birth to a baby in August.

When the trial finally began in September, prosecutors called former investors, partners and Theranos employees to testify. Jim Mattis, the retired four-star Marine Corps general and former defense secretary who was a Theranos director, took the stand, as did a former Theranos lab director who endured six grueling days of questioning. In one surreal moment, a forensics expert recited text messages between Ms. Holmes and her then-boyfriend and business partner at Theranos, Ramesh Balwani, who is known as Sunny.

This week, Alan Eisenman, an early investor in Theranos, testified that Ms. Holmes cut him off and threatened him when he asked her for more information about the company. Yet even after that treatment, Mr. Eisenman poured more money into the start-up, believing its seemingly fast-growing business would deliver riches to backers like him.

When asked about his understanding of the value of his Theranos stock today, Mr. Eisenman said, “It’s not an understanding, it’s a conclusion. It’s worth zero.”

Image

An email exchange between Sunny Balwani, the chief operating officer of Theranos, Ms. Holmes and the investor Alan Eisenman, presented during the trial.

The prosecution’s most compelling evidence included a series of validation reports that Ms. Holmes sent to potential investors and partners that made it look as though pharmaceutical companies including Pfizer and Schering-Plough had endorsed Theranos’s technology. Representatives from each company testified that they had not endorsed Theranos’s blood test and were surprised to see their companies’ logos added to the report.

Daniel Edlin, who worked at Theranos and was a fraternity brother of Ms. Holmes’s brother, Christian, testified that the start-up faked demonstrations of its machines for potential investors, hid technology failures and threw out abnormal blood test results.

Mr. Mattis testified that he was not aware of any contracts between Theranos and the military to put its machines on medevac helicopters or on the battlefield, as Ms. Holmes had frequently told investors.

Image

A Theranos report implied endorsements from pharmaceutical companies including Schering-Plough and Pfizer.

The prosecution concluded its case with testimony from Roger Parloff, the journalist who wrote a magazine cover story about Ms. Holmes, helping propel her to acclaim. Mr. Parloff’s article was sent to numerous investors as part of Ms. Holmes’s pitch.

Yet notably absent from the courtroom were some of the most prominent witnesses on the prosecution’s list. Ms. Holmes’s rise was aided by her association with business titans such as the media mogul Rupert Murdoch, elder statesmen such as Henry Kissinger and Admiral Gary Roughead, and the lawyer David Boies. Theranos was felled, in part, by whistle-blowers such as Tyler Shultz, the grandson of George Shultz, the former secretary of state who sat on Theranos’s board. None of them testified.

Also absent was Mr. Balwani, who was charged with fraud alongside Ms. Holmes and faces trial next year. His role as a fiery defender of Theranos who went after anyone who questioned the company has been in the background of much of the testimony.

At nearly every turn, Ms. Holmes’s lawyers sought to limit testimony and evidence. They attacked the credibility of investors, using legal disclaimers to show that investors knew they were gambling on a young start-up. The lawyers also poked holes in investors’ limited due diligence on Theranos’s claims. At one point, they directed Erika Cheung, a key whistle-blower who worked in Theranos’s lab, to read the entire organizational chart of the people employed in lab to show she played a small role in the overall operation.

The defense successfully argued to have one count of fraud against Ms. Holmes dropped. A patient who received a suspicious test from Theranos was barred from testifying earlier this month.

Ms. Holmes’s lawyers are likely to try to shine a spotlight on her relationship with Mr. Balwani. The two dated in secret. In court filings, Ms. Holmes alleged he was emotionally abusive and controlling. Mr. Balwani’s lawyers have denied the claims.

Testimony from Ms. Holmes is likely to revive the media circus surrounding the trial’s early days, which died down as the weeks of testimony wore on. It would also open her up to potentially damaging cross-examination from prosecutors or perjury.

“Most criminal defendants do not testify, particularly in white-collar cases where the government has many challenges to overcome, like in proving intent, and sometimes even in just proving that a crime occurred,” Mr. Spektor said. Ms. Holmes’s case is different, he said, because the offense is clear cut and the evidence is fairly easy to understand.

Throughout the proceedings, Ms. Holmes has been quiet in the courtroom, only whispering to her lawyers or family members. But the jury heard her forcefully defending Theranos against accusations of fraud in video interviews played in court. They also heard her accept blame.

“I’m the founder and C.E.O. of this company,” she said in one of the videos. “Anything that happens in this company is my responsibility.”

Leave a Reply